The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Open accessAbstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. Serology is considered key to population-level surveillance and potentially individual-level risk assessment. However, immunoassay performance has not been compared on large, identical sample sets. We aimed to investigate the performance of four high-throughput commercial SARS-CoV-2 antibody immunoassays and a novel 384-well ELISA. METHODS: We did a head-to-head assessment of SARS-CoV-2 IgG assay (Abbott, Chicago, IL, USA), LIAISON SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy), Elecsys Anti-SARS-CoV-2 assay (Roche, Basel, Switzerland), SARS-CoV-2 Total assay (Siemens, Munich, Germany), and a novel 384-well ELISA (the Oxford immunoassay). We derived sensitivity and specificity from 976 pre-pandemic blood samples (collected between Sept 4, 2014, and Oct 4, 2016) and 536 blood samples from patients with laboratory-confirmed SARS-CoV-2 infection, collected at least 20 days post symptom onset (collected between Feb 1, 2020, and May 31, 2020). Receiver operating characteristic (ROC) curves were used to assess assay thresholds. FINDINGS: At the manufacturers' thresholds, for the Abbott assay sensitivity was 92·7% (95% CI 90·2-94·8) and specificity was 99·9% (99·4-100%); for the DiaSorin assay sensitivity was 96·2% (94·2-97·7) and specificity was 98·9% (98·0-99·4); for the Oxford immunoassay sensitivity was 99·1% (97·8-99·7) and specificity was 99·0% (98·1-99·5); for the Roche assay sensitivity was 97·2% (95·4-98·4) and specificity was 99·8% (99·3-100); and for the Siemens assay sensitivity was 98·1% (96·6-99·1) and specificity was 99·9% (99·4-100%). All assays achieved a sensitivity of at least 98% with thresholds optimised to achieve a specificity of at least 98% on samples taken 30 days or more post symptom onset. INTERPRETATION: Four commercial, widely available assays and a scalable 384-well ELISA can be used for SARS-CoV-2 serological testing to achieve sensitivity and specificity of at least 98%. The Siemens assay and Oxford immunoassay achieved these metrics without further optimisation. This benchmark study in immunoassay assessment should enable refinements of testing strategies and the best use of serological testing resource to benefit individuals and population health. FUNDING: Public Health England and UK National Institute for Health Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Self-citationReport of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)
Gomes, C. A. (2020) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 2,134
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
Bryan, A., Pepper, G., Wener, M. H., Fink, S. L., Morishima, C., Chaudhary, A., Jerome, K. R., Mathias, P. C., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00941-20 · Cited by 527
Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2
Bao, L., Deng, W., Gao, H., Xiao, C., Liu, J., Xue, J., Lv, Q., Liu, J., Yu, P., Xu, Y., et al. (2020) · doi:10.1101/2020.03.13.990226 · Cited by 419
Cited by
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940
Self-citationPouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., et al. (2021) · doi:10.1101/2021.08.18.21262237 · Cited by 543
Self-citationAbani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00897-7 · Cited by 492
Self-citationSpike-antibody waning after second dose of BNT162b2 or ChAdOx1
Shrotri, M., Navaratnam, A. M. D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., Beale, S., Fong, W. L. E., Patel, P., Kovar, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01642-1 · Cited by 393
Abani, O., Abbas, A., Abbas, F., Abbas, M., Abbasi, S., Abbass, H., Abbott, A., Abdallah, N., Abdelaziz, A., Abdelfattah, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00163-5 · Cited by 369
Self-citation
Metadata
- Authors
- Ainsworth, M., Andersson, M., Auckland, K., Baillie, J. K., Barnes, E., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., Bown, A., Brooks, T., Burgess-Brown, N. A., Camara, S., Catton, M., Chau, K. K., Christott, T., Clutterbuck, E., Coker, J., Cornall, R. J., Cox, S., Crawford-Jones, D., Crook, D. W., D'Arcangelo, S., Dejnirattsai, W., Dequaire, J. M. M., Dimitriadis, S., Dingle, K. E., Doherty, G., Dold, C., Dong, T., Dunachie, S. J., Ebner, D., Emmenegger, M., Espinosa, A., Eyre, D. W., Fairhead, R., Fassih, S., Feehily, C., Felle, S., Fernandez-Cid, A., Fernandez Mendoza, M., Foord, T. H., Fordwoh, T., Fox McKee, D., Frater, J., Gallardo Sanchez, V., Gent, N., Georgiou, D., Groves, C. J., Hallis, B., Hammond, P. M., Hatch, S. B., Harvala, H. J., Hill, J., Hoosdally, S. J., Horsington, B., Howarth, A., James, T., Jeffery, K., Jones, E., Justice, A., Karpe, F., Kavanagh, J., Kim, D. S., Kirton, R., Klenerman, P., Knight, J. C., Koukouflis, L., Kwok, A., Leuschner, U., Levin, R., Linder, A., Lockett, T., Lumley, S. F., Marinou, S., Marsden, B. D., Martinez, J., Martins Ferreira, L., Mason, L., Matthews, P. C., Mentzer, A. J., Mobbs, A., Mongkolsapaya, J., Morrow, J., Mukhopadhyay, S. M. M., Neville, M. J., Oakley, S., Oliveira, M., Otter, A., Paddon, K., Pascoe, J., Peng, Y., Perez, E., Perumal, P. K., Peto, T. E. A., Pickford, H., Ploeg, R. J., Pollard, A. J., Richardson, A., Ritter, T. G., Roberts, D. J., Rodger, G., Rollier, C. S., Rowe, C., Rudkin, J. K., Screaton, G., Semple, M. G., Sienkiewicz, A., Silva-Reyes, L., Skelly, D. T., Sobrino Diaz, A., Stafford, L., Stockdale, L., Stoesser, N., Street, T., Stuart, D. I., Sweed, A., Taylor, A., Thraves, H., Tsang, H. P., Verheul, M. K., Vipond, R., Walker, T. M., Wareing, S., Warren, Y., Wells, C., Wilson, C., Withycombe, K., & Young, R. K.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 20
- Issue
- 12
- Pages
- 1390-1400
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W3087639085
- Cited by
- 351
- References
- 25
- FWCI
- 9.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. https://app.cochat.ai/papers/10.1016/s1473-3099(20)30634-4
- The paper
- Ainsworth, M., Andersson, M., Auckland, K., Baillie, J. K., Barnes, E., Beer, S., Beveridge, A., Bibi, S., Blackwell, L., Borak, M., Bown, A., Brooks, T., Burgess-Brown, N. A., Camara, S., Catton, M., Chau, K. K., Christott, T., Clutterbuck, E., Coker, J., . . . Young, R. K. (2020). Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(20)30634-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.